Full Press Release Details
Aditxt Announces Pricing of $20.0 Million Public
RICHMOND, Va., - September 16, 2022 -
Aditxt, Inc., (Nasdaq: ADTX) (the "Company" or "Aditxt"), a biotech innovation company developing and commercializing
technologies focused on monitoring and modulating the immune system, today announced the pricing of a public offering of 3,333,333 shares
of its common stock (or common stock equivalents in lieu thereof), together with warrants to purchase up to 3,333,333 shares of its common
stock at a combined offering price to the public of $6.00 per share (or common stock equivalent) and associated warrants. The warrants
will have an exercise price of $6.00 per share, are exercisable immediately upon issuance, and will expire five years following the date
of issuance. The closing of the offering is expected to occur on or about September 20, 2022, subject to the satisfaction of customary
H.C. Wainwright & Co. is acting as the exclusive
placement agent for the offering.
The gross proceeds to the Company from the offering
are expected to be approximately $20.0 million, before deducting the placement agent's fees and other offering expenses payable
by the Company. The Company intends to use the net proceeds from this offering for general corporate purposes, which may include research
and development expenses, capital expenditures, working capital and general and administrative expenses, and potential acquisitions of
or investments in businesses, products and technologies that complement our business, although the Company has no present commitments
or agreements to make any such acquisitions or investments.
The securities described above are being offered
pursuant to a registration statement on Form S-1 (File No. 333-266183) initially filed with the Securities and Exchange Commission (SEC)
on July 18, 2022and became effective on September 16, 2022. The public offering is being made only by means of a prospectus, which forms
a part of the effective registration statement. When available, electronic copies of the final prospectus may be obtained for free on
the SEC's website located at http://www.sec.gov and may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park
Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.
This press release does not constitute an offer
to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities
in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or other jurisdiction.
Aditxt is a biotech innovation
company developing and commercializing technologies focused on monitoring and modulating the immune system. Aditxt's immune monitoring
technologies are designed to provide a personalized immune profile. Aditxt's immune modulating technologies, currently preclinical,
are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases
and allergies. For more information, please visit www.Aditxt.com and www.AditxtScore.com
Forward-Looking Statements
in this press release constitute "forward-looking statements" within the meaning of federal securities laws. Forward-looking
statements in this press release include, without limitation, the ability of the Company to close the offering and the use of proceeds
therefrom. Forward-looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or
current expectations concerning, among other things, the Company's ongoing and planned product and business development; the Company's
intellectual property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue;
the Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry
in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees
of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of
various important factors, as well as market and other conditions and those risks more fully discussed in the section titled "Risk
Factors" in the Company's most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other
important factors in the Company's other filings with the Securities and Exchange Commission. All such statements speak only as of the
date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of
new information, future events or otherwise, except as required by law.
Media and Investor Relations Contact: